Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Rinsho Ketsueki ; 61(11): 1590-1594, 2020.
Artículo en Japonés | MEDLINE | ID: mdl-33298651

RESUMEN

A 47-year-old man was diagnosed with acute promyelocytic leukemia (APL) accompanied by pancytopenia and left forearm swelling. Complete remission was achieved with remission induction therapy using all-trans retinoic acid (ATRA), and consolidation therapy was completed. Three months after the treatment, left ear closure was observed, and a mass lesion was found in the left external auditory canal. An initial tumor biopsy only revealed inflammatory cell infiltration. Moreover, the tumor's rebiopsy performed 3 months later revealed MPO-positive and CD68-positive granulocyte infiltration. Furthermore, the rebiopsy revealed 4.9×105 copies/µgRNA of PML/RARα, the patient was diagnosed with locally recurrent APL. A bone marrow examination 2 weeks later confirmed an increase in myeloblasts and promyelocytes for the first time since the confirmation of remission. Therefore, it was diagnosed as bone marrow recurrence. Reinduction therapy using ATRA and arsenic trioxide again led to complete remission, after which autologous peripheral blood stem cell transplantation was performed. Currently, complete remission is being maintained. In this case, the recurrence of the external auditory canal lesion preceded the bone marrow recurrence. Therefore, it is important to note the nonspecific leukemia recurrence patterns of the external auditory canal.


Asunto(s)
Leucemia Promielocítica Aguda , Sarcoma Mieloide , Trióxido de Arsénico , Conducto Auditivo Externo , Humanos , Leucemia Promielocítica Aguda/diagnóstico , Leucemia Promielocítica Aguda/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Recurrencia , Sarcoma Mieloide/diagnóstico , Sarcoma Mieloide/tratamiento farmacológico , Tretinoina/uso terapéutico
2.
Stapp Car Crash J ; 61: 373-395, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29394446

RESUMEN

This study addresses the virtual optimization of the technical specifications for a recently developed Advanced Pedestrian Legform Impactor (aPLI). The aPLI incorporates a number of enhancements for improved lower limb injury predictability with respect to its predecessor, the FlexPLI. It also incorporates an attached Simplified Upper Body Part (SUBP) that enables the impactor's applicability to evaluate pedestrian's lower limb injury risk also with high-bumper cars. The response surface methodology was applied to optimize both the aPLI's lower limb and SUBP specifications, while imposing a total mass upper limit of 25 kg that complies with international standards for maximum weight lifting allowed for a single operator in the laboratory setting. All parameters were virtually optimized considering variable interaction, which proved critical to avoid misleading specifications. The results from this study can be used to construct physical aPLIs that are expected to be used in future car-to-pedestrian crash safety testing programs worldwide.


Asunto(s)
Accidentes de Tránsito , Diseño de Equipo , Traumatismos de la Pierna , Maniquíes , Peatones , Humanos , Modelos Biológicos
3.
Intern Med ; 55(4): 347-52, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26875958

RESUMEN

OBJECTIVE: Adherence to rehabilitation exercise is much lower in patients with hematologic malignancies (22.5-45.8%) than in patients with solid tumors (60-85%) due to the administration of more intensive chemotherapeutic regimens in the former. Virtual reality exercise can be performed even in a biological clean room and it may improve the adherence rates in elderly patients with hematologic malignancies. Thus, in this pilot study, we aimed to investigate the feasibility and safety of virtual reality exercise intervention using Nintendo Wii Fit in patients with hematologic malignancies receiving chemotherapy. METHODS: In this feasibility study, 16 hospitalized patients with hematologic malignancies aged ≥60 years performed virtual reality exercise for 20 minutes using the Nintendo Wii Fit once a day, five times a week, from the start of chemotherapy until hospital discharge. The adherence rate, safety, and physical and psychological performances were assessed. RESULTS: The adherence rate for all 16 patients was 66.5%. Nine patients completed the virtual reality exercise intervention with 88 sessions, and the adherence rate was 62.0%. No intervention-related adverse effects >Grade 2, according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0, were observed. We noted maintenance of the physical performance (e.g., Barthel index, handgrip strength, knee extension strength, one-leg standing time, and the scores of timed up and go test and Instrumental Activities of Daily Living) and psychosocial performance (e.g., score of hospital anxiety and depression scale). CONCLUSION: Virtual reality exercise using the Wii Fit may be feasible, safe and efficacious, as demonstrated in our preliminary results, for patients with hematologic malignancies receiving chemotherapy.


Asunto(s)
Enfermedad de Hodgkin/rehabilitación , Leucemia/rehabilitación , Linfoma no Hodgkin/rehabilitación , Terapia de Exposición Mediante Realidad Virtual , Actividades Cotidianas , Anciano , Terapia por Ejercicio/métodos , Estudios de Factibilidad , Femenino , Enfermedad de Hodgkin/psicología , Humanos , Leucemia/psicología , Linfoma no Hodgkin/psicología , Masculino , Persona de Mediana Edad , Selección de Paciente , Modalidades de Fisioterapia , Estudios Prospectivos , Resultado del Tratamiento , Juegos de Video , Terapia de Exposición Mediante Realidad Virtual/métodos
4.
Int J Med Inform ; 85(1): 76-9, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26520235

RESUMEN

INTRODUCTION: EGMAIN-GX is the computerized physician order entry system used in Japan. The automatic rounding-off of the calculated dose of chemotherapeutic drugs is an update in version 4, compared to version 2. We conducted a comparative study between EGMAIN-GX versions 2 and 4 to estimate the effect of the automatic rounding-off function on ordering time and dose dispersion. METHODS: Twelve hematologists ordered 5 predefined chemotherapeutic regimens most commonly used in treating hematologic malignancies, twice for each regimen. RESULTS: EGMAIN-GX version 4 significantly reduced ordering times compared to version 2 (635s vs. 259s, p<0.01). EGMAIN-GX version 4 also yielded a significantly higher ratio of actual to ideal doses of chemotherapeutic drugs than did version 2 (1.0097 and 0.9997, respectively; p<0.01) and a lower standard deviation (0.0275 and 0.0290, respectively). CONCLUSIONS: The automatic rounding-off function could decrease the ordering time and dose dispersion of chemotherapeutic drugs.


Asunto(s)
Antineoplásicos/uso terapéutico , Automatización , Neoplasias Hematológicas/tratamiento farmacológico , Sistemas de Entrada de Órdenes Médicas , Antineoplásicos/administración & dosificación , Humanos
5.
Asian Pac J Cancer Prev ; 15(15): 6177-80, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25124594

RESUMEN

BACKGROUND: Our study objectives were to evaluate the medical economics of cervical cancer prevention and thereby contribute to cancer care policy decisions in Japan. METHODS: Model creation: we created presence- absence models for prevention by designating human papillomavirus (HPV) vaccination for primary prevention of cervical cancer. Cost classification and cost estimates: we divided the costs of cancer care into seven categories (prevention, mass-screening, curative treatment, palliative care, indirect, non-medical, and psychosocial cost) and estimated costs for each model. Cost-benefit analyses: we performed cost-benefit analyses for Japan as a whole. RESULTS: HPV vaccination was estimated to cost $291.5 million, cervical cancer screening $76.0 million and curative treatment $12.0 million. The loss due to death was $251.0 million and the net benefit was -$128.5 million (negative). CONCLUSION: Cervical cancer prevention was not found to be cost-effective in Japan. While few cost-benefit analyses have been reported in the field of cancer care, these would be essential for Japanese policy determination.


Asunto(s)
Infecciones por Papillomavirus/economía , Vacunas contra Papillomavirus/economía , Neoplasias del Cuello Uterino/economía , Neoplasias del Cuello Uterino/prevención & control , Vacunación/economía , Adolescente , Adulto , Análisis Costo-Beneficio , Detección Precoz del Cáncer , Femenino , Estudios de Seguimiento , Papillomavirus Humano 16/aislamiento & purificación , Papillomavirus Humano 16/patogenicidad , Humanos , Modelos Económicos , Estadificación de Neoplasias , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/virología , Vacunas contra Papillomavirus/uso terapéutico , Participación del Paciente , Pronóstico , Años de Vida Ajustados por Calidad de Vida , Neoplasias del Cuello Uterino/virología , Adulto Joven
6.
Cancer Med ; 3(6): 1539-43, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25060622

RESUMEN

Cancer creates a tremendous financial burden. Cancer-related costs are categorized into direct, indirect, and psychosocial costs. Although there have been many reports on medical care costs, which are direct, those on other costs are extremely scarce. We estimated travel time and costs required for cancer patients to receive outpatient treatment. We studied 521 cancer patients receiving anti-cancer treatment between February 2009 and December 2012 at the Outpatient Chemotherapy Center of Teikyo University Chiba Medical Center. Address data were extracted from Data Warehouse electronic medical records, and travel distance and time required for outpatient treatment were calculated via MapInfo and ACT Distance Calculator Package. Transportation costs were estimated on the basis of ¥274 (=$3.00) per kilometer. The study design was approved by an ethics review board of Teikyo University (12-851). Average round-trip travel distance, time, and cost for all patients were 26.7 km, 72.5 min, and ¥7,303 ($79.99), respectively. Cancer patients incurred a travel cost of ¥4000-¥9000 ($40.00 to $100.00) for each outpatient treatment. With population aging, seniors living alone and senior households are increasing, and outpatient visits are becoming a common burden.


Asunto(s)
Atención Ambulatoria/economía , Neoplasias/economía , Neoplasias/terapia , Adulto , Anciano , Anciano de 80 o más Años , Registros Electrónicos de Salud , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Pacientes Ambulatorios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...